CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Operating Activities
Net loss	$ (102,496)	$ (88,720)	$ (75,738)
Adjustments for non-cash items:
Depreciation and amortization	105,502	109,375	85,737
Accretion of debt discount and debt issuance costs	19,415	17,673	15,629
Loss on prepayment of Senior Notes	5,938	5,777
Provision for inventory obsolescence	2,673	1,179	224
(Gain) loss on disposal of property and equipment	(271)		38
Stock-based compensation	13,016	17,172	14,228
Change in fair value of contingent consideration	(8,024)	1,637	(1,584)
Deferred income taxes		23,632	(41,354)
Gain on divestiture of Lazanda	(17,064)
Acquired in-process research and development	24,900		25,000
Other	240	611	358
Changes in assets and liabilities:
Accounts receivable	30,137	(30,931)	(44,117)
Receivables from collaborative partners	(30)	29	508
Inventories	(1,873)	(3,718)	9,329
Prepaid and other assets	(5,114)	(2,464)	6,085
Income taxes receivable		6,359	(2,332)
Accounts payable and other accrued liabilities	(6,436)	5,862	59,019
Accrued rebates, returns and discounts	4,292	10,478	85,348
Interest payable	(2,705)	(2,747)	15,992
Income taxes payable	67	59
Net cash provided by operating activities	62,167	71,263	152,370
Investing Activities
Purchases of property and equipment	(666)	(2,860)	(1,715)
Acquisition of a business			(1,050,011)
Acquisition of in-process research and development			(25,000)
Proceeds from disposal of property and equipment	280
Purchases of marketable securities	(8,277)	(68,818)	(116,209)
Maturities of marketable securities	66,557	115,207	84,884
Sales of marketable securities		2,007
Net cash provided (used in) by investing activities	57,894	45,536	(1,108,051)
Financing Activities
Proceeds from issuance of Senior Notes			562,063
Payment of contingent consideration liability	(1,673)	(1,783)	(1,041)
Senior Notes issuance costs			(511)
Repayment of Senior Notes	(110,000)	(100,000)
Fees for early repayment and modifications of Senior Notes	(7,400)	(5,000)
Proceeds from issuance of common stock	8,940	9,951	10,398
Shares withheld for payment of employee's withholding tax liability	(753)	(3,342)	(2,812)
Net cash (used in) provided in financing activities	(110,886)	(100,174)	568,097
Net increase (decrease) in cash and cash equivalents	9,175	16,625	(387,584)
Cash and cash equivalents at beginning of year	117,709	101,084	488,668
Cash and cash equivalents at end of period	126,884	117,709	101,084
Supplemental Disclosure of Cash Flow Information
Net cash paid (received) for income taxes	121	(14,425)	(4,048)
Cash paid for interest	55,542	71,093	39,511
Non-cash consideration for in-process research and development	19,900		$ 29,900
Accrued in-process research and development expenses	$ 5,000
Capitalized expenditures incurred but not yet paid		$ 402